• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Genmab

1,594.00 DKK

-1.54 %

Less than 1K followers

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-1.54 %
-5.34 %
-6.37 %
-21.36 %
-20.89 %
+7.63 %
-40.19 %
-41.03 %
+4,574.49 %

Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.

Read more
Market cap
99.39B DKK
Turnover
153.99M DKK
Revenue
23.65B
EBIT %
28.63 %
P/E
16.17
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
6.8
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release3 hours ago

Major Shareholder Announcement

Genmab
HCA Morgenbørs 15/06 - Udsigt til fredsaftale udløser stigninger
Video12 hours ago by
Victor Skriver, Michael Friis

HCA Morgenbørs 15/06 - Udsigt til fredsaftale udløser stigninger

Udsigt til en køb alt dag på god SpaceX børsnotering samt udsigt til fredsaftale. Herhjemme fokus vindere/tabere af fredsaftale, Lundbeck og PEG-

TormHafniaA.P. Møller - MærskGN Store NordFLSmidth & Co.LundbeckPharma Equity GroupGenmabDanske BankRockwoolVestas Wind Systems
Press release6/13/2026, 4:45 PM

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/11/2026, 5:16 PM

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab
Press release6/11/2026, 2:45 PM

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Genmab
HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk
Video6/3/2026, 7:29 AM by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk

I dagens Morgenbørs kigger vi ind i overvejende negative markeder, hvor USA-Iran konflikten igen synes at skygge for AI-euforien. Fokus herhjemme på Genmab og Novo Nordisk.

Novo NordiskGenmabDanish Aerospace and Defence CompanyHafniaFLSmidth & Co.BioMar GroupSwiss Properties InvestDSVRockwoolAmbuBavarian Nordic
HCA Morgenbørs 02/06 - Fokus på AI og software
Video6/2/2026, 7:12 AM by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 02/06 - Fokus på AI og software

I dagens Morgenbørs ser vi ind i en positiv start på dagen på fornyet fredshåb.

Netcompany GroupRockwoolGenmabPandora
HCA Morgenbørs 01/06 - Europa ned på manglende fredsaftale og resten af verden op på AI
Video6/1/2026, 7:16 AM by
Rasmus Køjborg, Michael Friis

HCA Morgenbørs 01/06 - Europa ned på manglende fredsaftale og resten af verden op på AI

I dagens Morgenbørs ser vi ind i blandede futures - Europa ned på manglende fredsaftale, og resten af verden op på AI. Herhjemme bl.a. fokus på Zealand, Genmab, IT konsulenter, Novonesis.

GenmabDanish Aerospace and Defence CompanyZealand PharmaBioMar GroupNovonesisCurasightTrifork GroupNetcompany Group
Regulatory press release5/29/2026, 8:34 PM

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab
HCA Morgenbørs 22/05 - Fredshåb og teknologi trækker op
Video5/22/2026, 7:15 AM by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 22/05 - Fredshåb og teknologi trækker op

I dagens Morgenbørs ser vi ind i positive futures fra morgenstunden, Fredshåb og teknologi trækker op. Herhjemme er der bl.a. fokus på Novo, ISS og GN.

ISSNovo NordiskGN Store NordParken Sport & EntertainmentGenmabGubra
Press release5/21/2026, 9:00 PM

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab
Regulatory press release5/12/2026, 5:46 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab
Regulatory press release5/8/2026, 7:05 PM

Major Shareholder Announcement

Genmab
HCA Morgenbørs 08/05 - Fokus herhjemme på bl.a. Novo Nordisk, Genmab, Maersk, Vestas og NNIT
Video5/8/2026, 7:21 AM by
Rasmus Køjborg

HCA Morgenbørs 08/05 - Fokus herhjemme på bl.a. Novo Nordisk, Genmab, Maersk, Vestas og NNIT

I dagens Morgenbørs ser vi ind i nye fald efter kursrekorderne i onsdags. Fokus herhjemme på bl.a. Novo Nordisk, Genmab, Maersk, Vestas og NNIT.

A.P. Møller - MærskTormHafniaGenmabNovo NordiskVestas Wind SystemsNNIT
Regulatory press release5/7/2026, 3:01 PM

Genmab Announces Financial Results for the First Quarter of 2026

Genmab
Regulatory press release4/17/2026, 2:56 PM

Genmab A/S Share Capital Reduction

Genmab
Regulatory press release4/14/2026, 2:44 PM

Major Shareholder Announcement

Genmab
Regulatory press release4/14/2026, 10:22 AM

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Genmab
HCA Morgenbørs 14/04 - Markedet forsøger at løfte sig
Video4/14/2026, 7:25 AM by
Michael Friis

HCA Morgenbørs 14/04 - Markedet forsøger at løfte sig

I dagens Morgenbørs ser vi ind i et marked der prøver at løfte sig fra morgenstunden, hele verden følger et skib. Herhjemme fokus på bl.a. Novonesis, Genmab og Demant

DemantGenmabNovonesis
Press release4/13/2026, 1:35 PM

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab